Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
Real-time Estimate Tradegate  -  05:53:53 2023-02-02 am EST
35.23 EUR   +2.25%
12:47aFormycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Warburg Research gives a Sell rating
MD
01/30FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Barclays reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Medical Care : Frenova enrolls patients in initiative to build world's largest genomic registry targeting kidney disease

01/11/2021 | 05:04am EST

Press Release

January 11, 2021

Media Contact

Michael Gavin

  1. +49 6172 608-2978 michael.gavin@fresenius.com

Contact for analysts and investors

Dr. Dominik Heger

  1. +49 6172 609-2601dominik.heger@fmc-ag.com

www.freseniusmedicalcare.com

Fresenius Medical Care's Frenova enrolls patients in initiative to

build world's largest genomic registry targeting kidney disease

Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure, announced today that the company's Frenova division has enrolled the first participants in its new initiative to develop the largest renal-focused genomic registry in the world.

Along with this key milestone, the company also announced that Ali Gharavi, MD, Chief of the Division of Nephrology at Columbia University Irving Medical Center and Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons, will lead the project and provide scientific guidance as Principal Investigator.

As a contract clinical development services company dedicated exclusively to medicines and medical products in renal research, Frenova orchestrates studies within the clinical footprint of Fresenius Medical Care, which provides dialysis treatments to about 350,000 patients around the globe. The renal-focused genomic registry represents a new business line within Frenova, which is based in Fresenius Medical Care's Global Medical Office.

As part of its growth strategy 2025, Fresenius Medical Care is using digital technologies and the capability to analyze huge amounts of data to develop new forms of renal therapy.

Nephrology has been under-represented in clinical research, even as rapid progress in gene sequencing and analysis has led to advances in precision medicine and

Page 1/2

individualized care in oncology, cardiology and other medical areas. Frenova's new genomic registry will contain genetic sequencing data from chronic kidney disease patients worldwide, which will be used by researchers to improve the understanding of kidney disease. Frenova developed the registry after researchers identified the lack of a large-scale,renal-focused registry of genomic and clinical data as a major impediment to kidney disease research.

"The new Frenova registry will close this gap by generating data that adds a clinical and genetic backbone to help support and fuel scientific innovation," said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. "The evidence for genetic drivers in kidney diseases is substantial, but much larger data sets will be needed to untangle the complex interactions that lead to kidney injury. By combining clinical and genetic sequencing data from ethnically and pathologically diverse participants, this genomic and phenotypic research resource will help scientists better understand how genetic variations in patients can lead to more precise diagnoses and therapies that help improve outcomes by individualizing care."

"Our renal-focused genomic registry will be a sustainable and comprehensive tool for kidney-focused research," said Kurt Mussina, President of Frenova. "It will bring patients, their families, patient advocacy groups, physicians and researchers together in the common cause of improving the lives of people living with kidney disease."

Learn more about Frenova Renal Research at https://www.frenova.com

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,073 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 349,167 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Page 2/2

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 11 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2021 10:03:01 UTC


ę Publicnow 2021
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
12:47aFormycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Warburg R..
MD
01/30FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Barclays ..
MD
01/27European Equities Move Lower Friday, Set to End Week in Negative Territory
MT
01/27FMC FRESENIUS MEDICAL CARE AG & CO KGAA : JP Morgan..
MD
01/25FMC FRESENIUS MEDICAL CARE AG & CO KGAA : UBS reite..
MD
01/22Study: Share of women on DAX boards rises to around 23 percent
DP
01/20Fresenius Medical Care : takes action to close global health gaps, signs “Zero Healt..
PU
01/18Fresenius Medical Care : Kepler 22. German Corporate Conference
PU
01/16German Shares Advance To Green Amid More Signs Of Cooling Inflation
MT
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials
Sales 2022 19 463 M 21 251 M 21 251 M
Net income 2022 704 M 768 M 768 M
Net Debt 2022 11 132 M 12 155 M 12 155 M
P/E ratio 2022 14,4x
Yield 2022 3,14%
Capitalization 12 484 M 13 630 M 13 630 M
EV / Sales 2022 1,21x
EV / Sales 2023 1,15x
Nbr of Employees 122 758
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 34,45 €
Average target price 32,78 €
Spread / Average Target -4,84%
EPS Revisions
Managers and Directors
Helen Giza Chief Executive & Financial Officer
Dieter Schenk Chairman-Supervisory Board
Franklin W. Maddux Executive VP-Clinical & Scientific Affairs
Rolf Allan Classon Vice Chairman-Supervisory Board
Pascale Witz Member-Supervisory Board